CEACAM5 and neoplasm: Our CEA-CAR design aimed to address TME complexities by incorporating a PD1x splice variant, acting as a competitive inhibitor to disrupt endogenous PD1-PD1 ligand interactions within the TME, thereby enhancing tumor-specific responses.